When our dog falls ill, needs surgical intervention, or simply requires a routine deworming treatment, owners blindly trust that the prescribed medication will be the right one without causing collateral damage. However, veterinary pharmacogenetics demonstrates that not all animals metabolize medications in the same way.
What is perfectly safe for one dog breed or individual can become toxic or completely ineffective for another due to genetic variations invisible to the naked eye. Understanding this biological factor completely changes the way we care for the health of our loyal companions.
Understanding the MDR1 Mutation
Building on the well-known issue analyzed in the article about the MDR1 mutation in dogs and how it affects them (the famous alteration in the ABCB1 gene that prevents certain drugs from being expelled from the brain), we expand our focus to how this is not an isolated exception, but part of a broad spectrum of pharmacological sensitivities.
Very common in breeds such as the Collie or the Border Collie. This alteration prevents the organism from properly expelling certain drugs from the brain, turning common compounds into potentially neurotoxic substances.
Far from being an isolated exception, the MDR1 mutation is merely the tip of the iceberg in a broad spectrum of pharmacological sensitivities.
To put it simply, imagine that your pet's body has transport proteins and liver enzymes that act as a biological customs checkpoint. When certain genetic variants exist, that "customs checkpoint" fails: the organism is unable to process, filter, or eliminate common active ingredients, causing toxic accumulations in the tissues.
Pharmacological Compatibility with Koko Genetics
At Koko Genetics, we know that caring for your dog's health begins with a better understanding of its biology. That is why our Advanced dog DNA test includes a pharmacogenetics analysis that studies how your pet's organism might respond to commonly used veterinary medications:
· Antiparasitics: Some of the sensitivity reactions associated with variants in ABCB1/MDR1 have been described with medications commonly used for parasite control, such as ivermectin, milbemycin, selamectin, and moxidectin.
· Other veterinary medications: The alteration of P-glycoprotein function has also been linked to other compounds such as loperamide, ciclosporin, tacrolimus, and chemotherapeutic agents like doxorubicin, which are used in various veterinary clinical contexts.
Farewell to "Trial and Error"
Until recently, clinical practice often relied on the so-called "trial and error" method: administering a drug and monitoring whether the animal presented an adverse reaction in order to change course. Today, genetic information can provide an additional piece to help the veterinarian make more personalized decisions.
Knowing whether a dog presents variants related to sensitivity to certain drugs, such as those associated with the ABCB1/MDR1 gene, provides the veterinary professional with complementary information that can be useful when evaluating specific treatments—especially those medications whose distribution in the organism may be affected by P-glycoprotein function.
Genetics does not replace clinical evaluation or determine by itself how an animal will respond to a specific medication, but it can help identify predispositions and provide additional information for more informed veterinary management.
Ready to safeguard your loyal friend's health? Check out Koko Genetics' drug sensitivity report and discover how the Advanced dog DNA test transforms the safety of their treatments starting today.
